Hengrui Medicine: Citrate Sodium Blood Filtration Replacement Solution Approved for Market Launch

Hengrui Pharmaceuticals announced that its subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. has received a notice from the National Medical Products Administration approving the market launch of sodium citrate hemofiltration replacement solution. This drug is classified as a Class 4 chemical drug, with a specification of 5000ml, and is a prescription drug. The approved indication is for the replacement solution for continuous renal replacement therapy using local citrate anticoagulation, suitable for pediatric patients of all ages. The main ingredients of sodium citrate hemofiltration replacement solution are sodium chloride and sodium citrate, which have anticoagulant and buffering effects. The drug was developed by Baxter Pharmaceuticals and was first launched overseas in 2006, and gained approval for domestic market launch in May 2021. The approval of this product this time is treated as passing the evaluation of generic drug quality and efficacy consistency. As of now, the total research and development investment in the sodium citrate hemofiltration replacement solution project is approximately 8.57 million yuan.